R Djukanovic, S Homeyard, C Gratziou, J Madden, A Walls, S Montefort, D Peroni, R Polosa, S Holgate and P Howarth
Immunopharmacology Group, University Medicine, University of Southampton, United Kingdom.

To improve understanding of the mechanisms of action of oral corticosteroids in asthma, we have conducted a double-blind, placebo- controlled study with prednisolone (20 mg for 2 wk followed by 10 mg for 4 wk) or placebo in 14 and 13 atopic corticosteroid-naive asthmatic subjects, respectively. Before and after treatment subjects underwent bronchoscopy with bronchoalveolar lavage (BAL) and bronchial biopsy. Treatment with prednisolone, but not placebo, significantly reduced asthma symptoms (from mean +/- SEM total weekly score of 34 +/- 6.2 to 15.7 +/- 3.2, p = 0.02) and albuterol usage (from mean +/- SEM number of puffs/wk of 29.7 +/- 6.2 to 18.2 +/- 3.7, p = 0.01) and significantly increased FEV1 (from 89.8 +/- 4.4% to 99.3 +/- 4.1% of predicted, p = 0.03). There were no significant changes in inflammatory or epithelial cell counts, levels of T-cell activation or albumin concentration in BAL. However, immunohistochemistry of bronchial biopsies showed that in the submucosa prednisolone significantly decreased numbers of mast cells by 62% (from median 45 to 17/mm2, p = 0.01), eosinophils by 81% (from median 30.1 to 5.7/mm2, p = 0.004), and CD4+ T-cells by 68% (from median 64.6 to 18.5/mm2, p = 0.02). In the epithelium only the reduction in the numbers of eosinophils was significant (from median 1.1 to 0/mm of epithelium, p = 0.02). There were no significant changes in any cell counts in the subjects receiving placebo, and comparison of the changes between the treatment groups identified a significant prednisolone-related reduction in submucosal eosinophil and mast cell counts (p = 0.003 and 0.03, respectively). The temporal association between the clinical and physiologic improvement, and the correlation between the magnitude of change in CD4+ T-cell counts in the submucosa and increase in PC20 methacholine (rs = 0.60, p = 0.049) suggests that the reduction in airways inflammatory cell numbers underlies the clinical efficacy of oral corticosteroids.

This article has been cited by other articles:

				S. Siddiqui, F. Hollins, S. Saha, and C. E. Brightling Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur. Respir. J., December 1, 2007; 30(6): 1043 - 1056. [Abstract] [Full Text] [PDF]

				D. R. Dorscheid, B. J. Patchell, O. Estrada, B. Marroquin, R. Tse, and S. R. White Effects of corticosteroid-induced apoptosis on airway epithelial wound closure in vitro Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L794 - L801. [Abstract] [Full Text] [PDF]

				M. M. Kelly, J. Chakir, D. Vethanayagam, L.-P. Boulet, M. Laviolette, J. Gauldie, and P. M. O'Byrne Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest, September 1, 2006; 130(3): 741 - 753. [Abstract] [Full Text] [PDF]

				D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation. Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]

				C. Bergeron and L.-P. Boulet Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest, April 1, 2006; 129(4): 1068 - 1087. [Abstract] [Full Text] [PDF]

				P. Chanez, A. Bourdin, I. Vachier, P. Godard, J. Bousquet, and A. M. Vignola Effects of Inhaled Corticosteroids on Pathology in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 184 - 190. [Abstract] [Full Text] [PDF]

				R. Djukanovic, S. J. Wilson, M. Kraft, N. N. Jarjour, M. Steel, K. F. Chung, W. Bao, A. Fowler-Taylor, J. Matthews, W. W. Busse, et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 583 - 593. [Abstract] [Full Text] [PDF]

				N. W. Lukacs, A. Berlin, D. Schols, R. T. Skerlj, and G. J. Bridger AMD3100, a CxCR4 Antagonist, Attenuates Allergic Lung Inflammation and Airway Hyperreactivity Am. J. Pathol., April 1, 2002; 160(4): 1353 - 1360. [Abstract] [Full Text] [PDF]

				D. R. DORSCHEID, K. R. WOJCIK, S. SUN, B. MARROQUIN, and S. R. WHITE Apoptosis of Airway Epithelial Cells Induced by Corticosteroids Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1939 - 1947. [Abstract] [Full Text] [PDF]

				S. J. WILSON, A. WALLIN, G. DELLA-CIOPPA, T. SANDSTROM, and S. T. HOLGATE Effects of Budesonide and Formoterol on NF-kappa B, Adhesion Molecules, and Cytokines in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1047 - 1052. [Abstract] [Full Text] [PDF]

				P. G. GIBSON, N. SALTOS, and K. FAKES Acute Anti-inflammatory Effects of Inhaled Budesonide in Asthma . A Randomized Controlled Trial Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 32 - 36. [Abstract] [Full Text]

				E. A. BECKY KELLY, W. W. BUSSE, and N. N. JARJOUR Inhaled Budesonide Decreases Airway Inflammatory Response to Allergen Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 883 - 890. [Abstract] [Full Text]

				J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]

				S. PEDERSEN Why Does Airway Inflammation Persist? Is It Failure to Treat Early? Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S182 - 185. [Full Text] [PDF]

				R. LOUIS, L. C. K. LAU, A. O. BRON, A. C. ROLDAAN, and M. RADERMECKER The Relationship between Airways Inflammation and Asthma Severity Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 9 - 16. [Abstract] [Full Text]

				R. Hidi, V. Riches, M. Al-Ali, W. W. Cruikshank, D. M. Center, S. T. Holgate, and R. Djukanovic Role of B7-CD28/CTLA-4 Costimulation and NF-{kappa}B in Allergen-Induced T Cell Chemotaxis by IL-16 and RANTES J. Immunol., January 1, 2000; 164(1): 412 - 418. [Abstract] [Full Text] [PDF]

				M. LAVIOLETTE, K. MALMSTROM, S. LU, P. CHERVINSKY, J.-C. PUJET, I. PESZEK, J. ZHANG, and T. F. REISS Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1862 - 1868. [Abstract] [Full Text]

				J. L. FAUL, E. A. DEMERS, C. M. BURKE, and L. W. POULTER The Reproducibility of Repeat Measures of Airway Inflammation in Stable Atopic Asthma Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1457 - 1461. [Abstract] [Full Text]

				A. JATAKANON, C. UASUF, W. MAZIAK, S. LIM, K. F. CHUNG, and P. J. BARNES Neutrophilic Inflammation in Severe Persistent Asthma Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1532 - 1539. [Abstract] [Full Text]

				R J Meijer, H A M Kerstjens, L R Arends, H F Kauffman, G H Koëter, and D S Postma Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma Thorax, October 1, 1999; 54(10): 894 - 899. [Abstract] [Full Text]

				R G Stirling, S A Kharitonov, D Campbell, D S Robinson, S R Durham, K F Chung, and P J Barnes Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids Thorax, December 1, 1998; 53(12): 1030 - 1034. [Abstract] [Full Text]

				C. LAMBLIN, P. GOSSET, I. TILLIE-LEBLOND, F. SAULNIER, C.-H. MARQUETTE, B. WALLAERT, and A. B. TONNEL Bronchial Neutrophilia in Patients with Noninfectious Status Asthmaticus Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 394 - 402. [Abstract] [Full Text]